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Abstract 
Introduction 
Therapeutic hypothermia (TH) is often used to treat out of hospital cardiac arrest (OHCA) 
patients who also often simultaneously receive insulin for stress-induced hyperglycaemia. 
However, the impact of TH on systemic metabolism and insulin resistance in critical illness is 
unknown. This study analyses the impact of TH on metabolism, including the evolution of 
insulin sensitivity (SI) and its variability, in patients with coma after OHCA. 
Methods 
This study uses a clinically validated, model-based measure of SI. Insulin sensitivity was 
identified hourly using retrospective data from 200 post-cardiac arrest patients (8,522 hours) 
treated with TH, shortly after admission to the Intensive Care Unit (ICU). Blood glucose and 
body temperature readings were taken every one to two hours. Data were divided into three 
periods: 1) cool (T <35°C); 2) an idle period of two hours as normothermia was re-
established; and 3) warm (T >37°C). A maximum of 24 hours each for the cool and warm 
periods were considered. The impact of each condition on SI is analysed per cohort and per 
patient for both level and hour-to-hour variability, between periods and in 6-hour blocks. 
Results 
Cohort and per patient median SI levels increase consistently by 35% to 70% and 26% to 
59% (P <0.001) respectively from cool to warm. Conversely, cohort and per patient SI 
variability decreased by 11.1% to 33.6% (P <0.001) for the first 12 hours of treatment. 
However, SI variability increases between the 18th and 30th hours over the cool-warm 
transition, before continuing to decrease afterward. 
Conclusions 
OCHA patients treated with TH have significantly lower and more variable SI during the cool 
period, compared to the later warm period. As treatment continues, SI level rises, and 
variability decreases consistently except for a large, significant increase during the cool-warm 
transition. These results demonstrate increased resistance to insulin during mild induced 
hypothermia. Our study might have important implications for glycaemic control during 
targeted temperature management. 
Introduction 
Hyperglycaemia is prevalent in critical care [1-4] and increases the risks of further 
complications and mortality [1,4,5]. Glycaemic control has shown benefits in reducing 
mortality and morbidity [4,6,7]. However, many studies have found it difficult to reproduce 
these results [8-10] due in part to metabolic variability [11]. Out-of-Hospital Cardiac Arrest 
(OHCA) patients often experience hyperglycaemia [12,13]. These patients belong to one 
group who can be highly insulin resistant and variable, particularly on the first two days of 
stay [14], as well as those who may particularly benefit from glycaemic control [4]. 
Therapeutic hypothermia (TH) is often used with OHCA patients to protect against brain 
injury [15,16], which leads to a lowering of metabolic rate, reduce plasma insulin, induce 
insulin resistance and alter blood glucose homeostasis [17]. One of the adverse events 
associated with hypothermic therapy is a decrease in insulin sensitivity and endogenous 
insulin secretion [18]. However, this decrease may not be observable in a cohort who is 
already highly insulin resistant and variable [14]. Hence, understanding metabolic evolution 
and variability would enable safer and more accurate glycaemic control using insulin in this 
cohort. This study analyses the evolution of a clinically validated model-based measure of 
insulin sensitivity (SI) in OHCA patients to assess the impact of hypothermia therapy. 
Methods 
Patients and data 
A retrospective analysis of glycaemic control data from 200 OHCA patients (8522 hours) 
treated with TH, shortly after admission to Intensive Care. Data was obtained from Intensive 
Care Units at Christchurch Hospital, New Zealand, at Erasme Hospital, Belgium, and CHUV-
Lausanne Hospital, Switzerland. Patients from Christchurch Hospital (N = 20) were on the 
SPRINT glycaemic control protocol [7], whereas the remaining 180 patients from Erasme (N 
= 99) and Lausanne (N = 81) Hospitals were on local glycaemic control protocols and 
included in an institutional database (2008–2012). 
Blood glucose (BG) and temperature readings were taken 1–2 hourly. Data were divided into 
three periods: 1) cool (T < 35°C); 2) an idle period of 2 hours as normothermia was restored; 
and 3) warm (T > 37°C). A maximum of 24 contiguous hours and a minimum of 15 hours for 
each period were considered, ensuring a balance of contiguous data between periods. Overall 
demographics are shown in Table 1. 




Total patients, number (n) 200 
Median age, years 61 [51, 72] 
Female gender, number (%) 40 (20.6%) 
ICU mortality, number (%) 85 (45.6%) 
Diabetes status, number (%) 26 (13.0%) 
Total treatment, hours (h) 4219 4303 
Blood Glucose, median (mmol/L) 7.6 [6.3,9.7] 6.8 [5.9,8.0] 
Insulin Rate, median (U/hr) 3.4 [1.3,8.0] 3.5 [1.6,7.0] 
Glucose Rate, median (g/hr) 2.7 [1.0,5.3] 5.4 [2.7,8.1] 
IQR: Interquartile range. 
Glycaemic targets while treating OHCA patients in the three units were very similar and 
overlapped. The SPRINT protocol, used in the Christchurch Hospital ICU targeted 4.0-7.0 
mmol/L [7]. The protocol used in both the Erasme and Lausanne ICU’s differed from 
SPRINT, but targeted 6.0-8.0 mmol/L [17]. Although two different protocols were used in 
the three units, the targets were very similar and within the relatively tight 4.0-8.0 mmol/L 
range. 
Audit of the clinical data from SPRINT was given by the Upper S. Island Regional B Ethics 
Committee and for the data study by Taccone et al. [17], no approval was required as it was 
also a retrospective audit. 
Model-based insulin sensitivity 
Model-based SI in this study is a patient-specific parameter describing the overall whole-body 
effect of insulin. SI is identified for each hour, for each patient using a clinically validated 




















































Where G(t) represents the concentration of blood glucose (mmol/L). I(t) and Q(t) represent 
the plasma insulin and insulin interstitial concentrations (mU/L) respectively. Model 
parameters, rates and constants in this model were as fully defined in [21,24]. 
Model-based SI is identified hourly from patient data, producing an hourly piece-wise 
constant profile [25], capturing the whole-body glycaemic response to exogenous insulin and 
nutrition. The validity and independence of this patient-specific parameter have been 
validated using data from independent, clinically matched cohorts [19], in comparison to 
gold-standard insulin sensitivity tests [22] and in clinical glycaemic control [20,23]. 
Analyses and metrics 
SI level and variability during the cool (T ≤ 35°C) and warm (T > 35°C) periods are analysed 
on per-cohort and per-patient bases using 6-hour blocks of data as per Table 2. SI level is 
compared between blocks as a cohort median and by per-patient median SI. Similarly, SI 
variability is calculated as the hour-to-hour percentage change in SI and is analysed per-
cohort for each block. 
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The use of percentage change, rather than absolute change, normalises the metric so patients 
with differing SI levels can be compared fairly. 
  
Table 2 Descriptions of 6-hour blocks for data analysis 
Day Period Analysis Block Hour Range 
1 Cool 6-hour block 1 0 – 6 hours 
2 6 – 12 hours 
3 12 – 18 hours 
4 18 – 24 hours 
Idle 2 hour period in between cool and warm 
2 Warm 6-hour block 5 24 – 30 hours 
6 30 – 36 hours 
7 36 – 42 hours 
8 42 – 48 hours 
Bagshaw et al. [26] reported an association between both hypoglycaemia and BG variability 
with mortality during the first 24 hours of ICU stay. Thus, the acute evolution of SI over the 
first day using 6-hour blocks was analysed as SI variability is a key contributor to BG 
variability. For the cohort analysis, SI and ∆% SI data from all patients was grouped into each 
appropriate time-block. Median values for each time-block were calculated for comparison to 
the previous block, thus capturing overall cohort changes over time in level and hour-to-hour 
variability. 
For the per-patient analysis, the median value of SI and the interquartile range (IQR) of ∆% SI 
were calculated for each patient, for each time-block. The IQR captures the width or degree 
of variability for a given patient within each 6-hour block. Thus, a reduction in the IQR of 
∆% SI over time would indicate a reduction in hour-to-hour variability for a given patient. 
SI level and variability are non-Gaussian and thus compared using non-parametric statistics 
and cumulative distribution functions (CDFs). CDFs are particularly useful as they show the 
entire distribution that is often summarised as a median and IQR. The CDF for a given value 
of the independent variable (e.g. SI = x) describes the probability of observing a value less 
than or equal to x. All distributed data were compared using a Wilcoxon rank-sum test 
(Mann–Whitney U-test), except for SI variability results. SI variability was compared using 
the Kolmogorov-Smirnov (KS) test as it has greater power to detect differences in the shape 
of distributions when median values are similar. In all cases, p <0.05 is considered 
statistically significant. 
Results 
SI level analyses 
Figures 1 and 2 present the cumulative distribution functions (CDFs) of hourly SI level by 
cohort and median SI per-patient, respectively, using 6-hour blocks. Table 3 presents the 
increase in median insulin sensitivity and corresponding p-values between successive time 
blocks. 
Figure 1 Insulin sensitivity (SI) level distribution per-cohort for OHCA patients, treated 
with TH using 6-hour blocks for both cool and warm periods. 
Figure 2 Insulin sensitivity (SI) level distribution per-patient for OHCA patients, treated 
with TH using 6-hour blocks for both cool and warm periods. 
Table 3 Increasing cohort and per patient median SI during cool and warm as per 6-
hour blocks of data, where the p-values compare successive 6-hour blocks as shown in 
the first column for both the overall cohort and per-patient median values 
SI level Cohort analysis Per-patient analysis 
Analysis % SI Median Increase p-value % SI Median Increase p-value 
[6-hr blocks] 
Block 1–2 (C) 35.1 < 0.05 26.4 < 0.05 
(0–6 vs. 6–12 hr) 
Block 2–3 (C) 19.2 < 0.05 31.1 < 0.05 
(6–12 vs. 12–18 hr) 
Block 3–4 (C) 31.8 < 0.05 42.4 < 0.05 
(12–18 vs. 18–24 hr) 
Block 4–5 (C-W) 23.4 < 0.05 18.3 < 0.05 
(18–24 vs. 24–30 hr) 
Block 5–6 (W) 23.9 < 0.05 23.2 < 0.05 
(24–30 vs. 30–36 hr) 
Block 6–7 (W) 13.1 0.06 15.8 0.2 
(30–36 vs. 36–42 hr) 
Block 7–8 (W) 4.4 0.4 3.2 0.5 
(36–42 vs. 42–48 hr) 
P-values are calculated using Wilcoxon rank-sum test. 
The results suggest that SI increases for the cohort and per patient are statistically significant 
for the first 36 hours (p < 0.05) in both cases. 
Results in Figure 2, Figure 3 and Table 3 are further reflected in Table 4, which shows that SI 
increases for a large proportion of patients between 6-hour blocks over the first 36 hours of 
ICU stay. Table 4 also shows that after 48 hours of treatment, only 86% of patients show rise 
in SI from the first 6 hours. Thus, while the general trend is obvious for increasing SI, it is not 
guaranteed for all patients. Equally, these increases decelerate in terms of number of patients 
with increasing SI over time going from left to right in the table. 
Figure 3 Insulin sensitivity variability distribution (%∆SI) per-cohort for OHCA 
patients, treated with TH using 6-hour blocks for both cool and warm periods. 
  
Table 4 Proportion of patients for whom median insulin sensitivity increases between 
the blocks indicated in the row and columns 
 6 -12 hr 12-18 hr 18-24 hr 24-30 hr 30-36 hr 36-42 hr 42-48 hr 
0 – 6 hr 0.72 0.74 0.79 0.83 0.84 0.85 0.86 
6 – 12 hr  0.66 0.72 0.74 0.76 0.82 0.82 
12 – 18 hr   0.69 0.70 0.75 0.79 0.79 
18 – 24 hr    0.66 0.65 0.70 0.72 
24 – 30 hr     0.64 0.68 0.66 
30 – 36 hr      0.58 0.61 
36 – 42 hr       0.52 
SI variability analyses 
Figures 3 and 4 present the CDFs for changes in SI (%∆SI) for 6-hourly blocks per-cohort and 
50% range of SI variability per-patient, respectively. Table 5 presents the reductions between 
successive blocks. 
Figure 4 Per-patient 50% range of SI variability distribution of OHCA patients, treated 
with TH using 6-hour blocks for both cool and warm periods. 
Table 5 Reductions in the interquartile range and median SI per patient range of hour-
to-hour percentage SI change over time during cool and warm after as per 6-hour 
blocks of data, where the p-values compare successive 6-hour blocks as shown in the 
first column for both the overall cohort and per-patient median values 
SI Variability Cohort analysis Per-patient analysis 
Analysis % Reduction of IQR p-value % Median Decrease p-value 
[6-hr blocks] 
Block 1–2 (C) 11.1 < 0.05 33.6 < 0.05 
(0–6 vs. 6–12 hr) 
Block 2–3 (C) 20.7 < 0.05 15.8 < 0.05 
(6–12 vs. 12–18 hr) 
Block 3–4 (C) 14.4 < 0.05 22.6 < 0.05 
(12–18 vs. 18–24 hr) 
Block 4–5 (C-W) −19.7 < 0.05 −14.9 < 0.05 
(18–24 vs. 24–30 hr) 
Block 5–6 (W) 23.1 < 0.05 26.4 0.05 
(24–30 vs. 30–36 hr) 
Block 6–7 (W) 4.6 < 0.05 0.8 0.05 
(30–36 vs. 36–42 hr) 
Block 7–8 (W) 13.0 0.08 17.1 0.06 
(36–42 vs. 42–48 hr) 
P-values are calculated using Kolmogorov-Smirnov test. 
Cohort and per-patient variability decreases for the first 24 hours. However, it increases 
across the cool to warm transition, indicating some potential stress across the cool-warm 
transition with negative reductions. The decreasing trend returns for all subsequent blocks. 
The results suggest that %∆SI decreases per-cohort and per-patient are statistically significant 
(p < 0.05) for the first 36 hours in both cases. 
Discussion 
Insulin sensitivity level 
The SI level results for both per-cohort and per-patient analysis suggest that OHCA patients 
undergoing hypothermic treatment have significantly lower SI during the earlier cool period 
on day 1 than the later warm period on day 2. Both results determine the general trend for 
overall increasing SI level for critically ill patients over time and are consistent with other 
ICU studies [14,27]. Further analysis shows that the increase in SI level during the first 36 
hours are large and statistically significant for this cohort. The rapid increases in SI level for 
the first 36 hours is likely due to significant restart of human physiological systems and 
metabolic activities for these patients [13]. After 36 hours, the rapid SI increase abates as the 
patients’ metabolism improves and becomes more stable. 
Insulin sensitivity variability 
Both per-cohort and per-patient analysis suggest that OHCA patients undergoing TH 
treatment have high initial variability that decreases over the first 36 hours. However, the 
cool to warm transition at 24 hours shows an increase in variability likely due to the change 
of physiological conditions as body temperature increase from cool to warm between 18 – 36 
hours. The lower decrease in SI variability after 36th hours onwards suggests that the patients’ 
metabolic condition has improved and become more stable. 
Further analysis and comparison of SI variability between general ICU patients [14] and 
OHCA patients, treated with TH shows that the main difference between them is the SI 
variability increase during the cool-warm transition period for the latter cohort. These SI 
variability results do not follow the same trend with other general ICU studies by Pretty et al. 
[14], and it is a unique finding for this cohort that could significantly impact glycaemic 
control and safety from hypoglycaemia. 
Implications for glycaemic control 
Clinically, these results have significant implications for managing glycaemia. Increased SI 
variability leads to increased variability in BG level for a given insulin intervention [11]. 
With low and variable insulin sensitivity, glycaemic levels might appear to remain unchanged 
and difficult to control effectively with exogenous insulin. This situation may result in 
increased glycaemic variability as well as an increased risk of hyperglycaemia and 
hypoglycaemia during the first 36 hours of treatment due to greater hour-to-hour SI 
variability with increased insulin resistance [17]. Thus, since glycaemic variability and 
hypoglycaemia are independent risk factors for the critically ill, it is important to understand 
and manage these patient-specific dynamics, especially those unique to a cohort, when 
implementing glycaemic control. This outcome is particularly important when OHCA 
patients transition from cool to warm. These results may also generalise to other areas where 
glycaemic control is applied to hypothermic patients, such as in the operating theatre. 
There are several ways that this low and variable insulin sensitivity could be managed during 
glycaemic control. Reducing exogenous insulin doses, coupled with modulation of the 
glucose content of nutrition would diminish the impact of sudden changes of insulin 
sensitivity on glycaemic outcome. Equally, increased blood glucose measurement frequency 
could improve control and reduce glycaemic variability. Accepting higher glycaemic targets 
during periods of increased variability would trade-off a reduced risk of hypoglycaemia 
against increased hyperglycaemia. Ultimately, the preferred method for any unit may be 
influenced by practical considerations, such as clinical workload. 
Limitations 
The parameters used in the glucose insulin system model are based on general ICU patients 
with normal body temperature conditions. Thus, the insulin sensitivity values derived during 
the cool period could be biased by modelling errors or un-modelled effects. However, as 
noted previously, the validity and independence of this patient-specific parameter has been 
validated using data from clinically matched cohorts and has been shown to correlate well in 
gold-standard insulin sensitivity tests. 
Insulin sensitivity variability is a key contributor to glycaemic variability. Sechterberger et al. 
[28] showed an association between high glycaemic variability and mortality is not present in 
diabetic cohorts. Thus, a subgroup analysis of diabetic OHCA patients in this study would be 
very interesting. However, only 26 of 200 (13%) OHCA patients in this study had previously 
diagnosed diabetes (Table 1), which is too few to enable a reliable analysis with these 
methods. Additionally, in this particular cohort undiagnosed diabetes or impaired glucose 
regulation [29] may confound such a sub-group. 
Conclusions 
This study analyses the metabolic evolution of OHCA patients treated with TH. These 
analyses characterize the metabolic impact of TH treatment on the level and variability of 
insulin sensitivity to inform control. 
Two main conclusions are drawn as a result for these cohorts. 
i) SI level is much lower during TH and consistently increases over time, both cool and warm 
periods. 
ii) Insulin sensitivity is more variable during the cool period and shows contrasting behavior 
during cool-warm transition period between 18 – 30 hours, which indicates that there are 
major changes in physiology and metabolic conditions between cool and warm as influenced 
by human body temperature. Otherwise, it decreases over time. 
Finally, this study shows the need for patient-specific glycemic management to ensure good 
control and safety during treatment. These results have significant potential clinical impact on 
the metabolic treatment of these patients, and changes in clinical therapy are required to 
safely treat patients as they transition from cool to warm. 
Key messages 
• OCHA patients treated with TH have significantly lower and highly variable SI during the 
first 24 hours of cool period, compared to later warm period in their ICU stay. 
• There is an overall trend of increasing SI over the first 36 hours, both per-cohort and per-
patient results. 
• SI variability decreases consistently over time, except for a large, statistically significant 
increase during the cool-warm transition at 24th hours. 
• This increase requires special consideration for glycaemic control as it increases risk of 
hypoglycaemia, BG variability and thus mortality. 
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